OTCMKTS:SCIE

SpectraScience Competitors

$0.0002
0.00 (0.00 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.01
Volume17.75 million shs
Average Volume221.03 million shs
Market Capitalization$176,734.00
P/E RatioN/A
Dividend YieldN/A
Beta0.96

Competitors

SpectraScience (OTCMKTS:SCIE) Vs. IMRSQ, ECTE, ULGX, AKSY, ESMC, and HRTT

Should you be buying SCIE stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to SpectraScience, including IMRIS (IMRSQ), Echo Therapeutics (ECTE), Urologix (ULGX), Aksys (AKSY), Escalon Medical (ESMC), and Heart Tronics (HRTT).

SpectraScience (OTCMKTS:SCIE) and IMRIS (OTCMKTS:IMRSQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares SpectraScience and IMRIS's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpectraScienceN/AN/AN/A
IMRISN/AN/AN/A

Earnings and Valuation

This table compares SpectraScience and IMRIS's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectraScienceN/AN/AN/AN/AN/A
IMRISN/AN/AN/AN/AN/A

Risk & Volatility

SpectraScience has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, IMRIS has a beta of -10.69, meaning that its share price is 1,169% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for SpectraScience and IMRIS, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpectraScience0000N/A
IMRIS0000N/A

Summary

SpectraScience beats IMRIS on 1 of the 1 factors compared between the two stocks.

SpectraScience (OTCMKTS:SCIE) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares SpectraScience and Echo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpectraScienceN/AN/AN/A
Echo TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares SpectraScience and Echo Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectraScienceN/AN/AN/AN/AN/A
Echo TherapeuticsN/AN/AN/AN/AN/A

Risk & Volatility

SpectraScience has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, meaning that its share price is 609% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for SpectraScience and Echo Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpectraScience0000N/A
Echo Therapeutics0000N/A

Summary

Echo Therapeutics beats SpectraScience on 1 of the 1 factors compared between the two stocks.

SpectraScience (OTCMKTS:SCIE) and Urologix (OTCMKTS:ULGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares SpectraScience and Urologix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpectraScienceN/AN/AN/A
UrologixN/AN/AN/A

Earnings and Valuation

This table compares SpectraScience and Urologix's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectraScienceN/AN/AN/AN/AN/A
UrologixN/AN/AN/AN/AN/A

Risk & Volatility

SpectraScience has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Urologix has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for SpectraScience and Urologix, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpectraScience0000N/A
Urologix0000N/A

Summary

Urologix beats SpectraScience on 1 of the 1 factors compared between the two stocks.

SpectraScience (OTCMKTS:SCIE) and Aksys (OTCMKTS:AKSY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for SpectraScience and Aksys, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpectraScience0000N/A
Aksys0000N/A

Risk & Volatility

SpectraScience has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Aksys has a beta of -6.76, meaning that its share price is 776% less volatile than the S&P 500.

Profitability

This table compares SpectraScience and Aksys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpectraScienceN/AN/AN/A
AksysN/AN/AN/A

Earnings and Valuation

This table compares SpectraScience and Aksys' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectraScienceN/AN/AN/AN/AN/A
AksysN/AN/AN/AN/AN/A

Summary

SpectraScience beats Aksys on 1 of the 1 factors compared between the two stocks.

Escalon Medical (OTCMKTS:ESMC) and SpectraScience (OTCMKTS:SCIE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Escalon Medical and SpectraScience, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Escalon Medical0000N/A
SpectraScience0000N/A

Earnings & Valuation

This table compares Escalon Medical and SpectraScience's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Escalon Medical$9.40 millionN/A$-650,000.00N/AN/A
SpectraScienceN/AN/AN/AN/AN/A

SpectraScience has lower revenue, but higher earnings than Escalon Medical.

Profitability

This table compares Escalon Medical and SpectraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Escalon Medical-15.54%-136.63%-26.09%
SpectraScienceN/AN/AN/A

Risk and Volatility

Escalon Medical has a beta of -0.86, meaning that its share price is 186% less volatile than the S&P 500. Comparatively, SpectraScience has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Summary

SpectraScience beats Escalon Medical on 4 of the 5 factors compared between the two stocks.

SpectraScience (OTCMKTS:SCIE) and Heart Tronics (OTCMKTS:HRTT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings for SpectraScience and Heart Tronics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpectraScience0000N/A
Heart Tronics0000N/A

Earnings and Valuation

This table compares SpectraScience and Heart Tronics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectraScienceN/AN/AN/AN/AN/A
Heart TronicsN/AN/AN/AN/AN/A

Profitability

This table compares SpectraScience and Heart Tronics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpectraScienceN/AN/AN/A
Heart TronicsN/AN/AN/A

Risk and Volatility

SpectraScience has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Heart Tronics has a beta of 1024.78, meaning that its share price is 102,378% more volatile than the S&P 500.

Summary

Heart Tronics beats SpectraScience on 1 of the 1 factors compared between the two stocks.


SpectraScience Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IMRIS logo
IMRSQ
IMRIS
0.5$0.01flat$447,000.00N/A0.00
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03flat$356,000.00N/A0.00
ULGX
Urologix
0.6$0.01flat$192,000.00N/A0.00
AKSY
Aksys
0.0$0.00flat$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.34flat$0.00$9.40 million-5.67Increase in Short Interest
Gap Up
HRTT
Heart Tronics
0.0$0.15flat$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00flat$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00flat$0.00N/A0.00
PECN
Photoelectron
0.2$0.03flat$0.00N/A0.00Increase in Short Interest
Trimedyne logo
TMED
Trimedyne
0.4$4.25flat$0.00$5.57 million0.00
XCRP
Xcorporeal
0.0$0.00flat$0.00N/A0.00
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.